Exelixis (EXEL) Net Income towards Common Stockholders (2010 - 2026)
Exelixis (EXEL) posted quarterly Net Income towards Common Stockholders of $210.5 million for Q2 2026, up 31.86% year-over-year from $159.6 million in Q2 2025, and down 13.93% quarter-over-quarter from $244.5 million in Q1 2026.
Analysis
Exelixis (EXEL) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Exelixis' Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at $210.5 million for Q2 2026.
- In Q2 2026, Net Income towards Common Stockholders rose 31.86% year-over-year to $210.5 million; the TTM figure through Apr 2026 stood at $833.4 million (up 29.5% YoY), while the FY2026 annual figure was $782.6 million, up 50.13% from the prior year.
- Net Income towards Common Stockholders for Q2 2026 stood at $210.5 million, down from $244.5 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $244.5 million in Q1 2026, with the low at -$30.2 million in Q4 2022.
- The 5-year median for Net Income towards Common Stockholders is $85.5 million (2023), against an average of $112.0 million.
- The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders tumbled 131.71% in 2022, then soared 11232.66% in 2024.
- Exelixis' Net Income towards Common Stockholders stood at -$30.2 million in 2022, then jumped by 383.43% to $85.5 million in 2023, then soared by 37.95% to $118.0 million in 2024, then soared by 64.09% to $193.6 million in 2025, then grew by 8.72% to $210.5 million in 2026.
- Business Quant data shows EXEL's Net Income towards Common Stockholders at $210.5 million in Q2 2026, $244.5 million in Q1 2026, and $193.6 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 212.05 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 212.05 Mn |
| Apr 3, 2026 | 210.47 Mn |
| Jan 2, 2026 | 244.53 Mn |
| Oct 3, 2025 | 193.58 Mn |
| Jul 4, 2025 | 184.85 Mn |
| Apr 4, 2025 | 159.62 Mn |
| Jan 3, 2025 | 139.86 Mn |
| Sep 27, 2024 | 117.97 Mn |
| Jun 28, 2024 | 226.12 Mn |
| Mar 29, 2024 | 37.32 Mn |
| Dec 29, 2023 | 85.52 Mn |
| Sep 29, 2023 | 1.04 Mn |
| Jun 30, 2023 | 81.18 Mn |
| Mar 31, 2023 | 40.03 Mn |
| Dec 30, 2022 | -30.17 Mn |
| Sep 30, 2022 | 73.21 Mn |
| Jul 1, 2022 | 70.67 Mn |
| Apr 1, 2022 | 68.57 Mn |
| Dec 31, 2021 | 95.17 Mn |
| Oct 1, 2021 | 38.20 Mn |